Pharmaniaga inks MOU with China’s CSPC
26 Jul 2023
Pharmaniaga Bhd‘s wholly-owned subsidiary Pharmaniaga LifeScience Sdn Bhd has entered into a memorandum of understanding (MOU) with CSPC Holdings Co Ltd to explore a collaboration in the research and development, manufacturing and commercialisation of pharmaceutical and biopharmaceutical products.
Pharmaniaga said in a bourse filing that CSPC Pharmaceutical Group Ltd is a leading pharmaceutical group in China, and listed on the Main Board of the Hong Kong Stock Exchange since 1994.
“CSPC mainly owns two business segments of finished drugs and bulk drugs, with innovative drugs as the core development strategy. CSPC currently has a strong product portfolio in the therapeutic areas of nervous system disease, oncology, anti-infective and cardiovascular disease,” it said.
At the lunch break, the trading stock of Pharmaniaga was up one sen or 2.47% to 41.5 sen a share on the back of 4.76 million shares traded.
Source: The Star
